RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer

Int J Oncol. 2023 Apr;62(4):51. doi: 10.3892/ijo.2023.5499. Epub 2023 Mar 3.

Abstract

The invasiveness of pancreatic cancer and its resistance to anticancer drugs define its malignant potential, and are considered to affect the peritumoral microenvironment. Cancer cells with resistance to gemcitabine exposed to external signals induced by anticancer drugs may enhance their malignant transformation. Ribonucleotide reductase large subunit M1 (RRM1), an enzyme in the DNA synthesis pathway, is upregulated during gemcitabine resistance, and its expression is associated with worse prognosis for pancreatic cancer. However, the biological function of RRM1 is unclear. In the present study, it was demonstrated that histone acetylation is involved in the regulatory mechanism related to the acquisition of gemcitabine resistance and subsequent RRM1 upregulation. The current in vitro study indicated that RRM1 expression is critical for the migratory and invasive potential of pancreatic cancer cells. Furthermore, a comprehensive RNA sequencing analysis showed that activated RRM1 induced marked changes in the expression levels of extracellular matrix‑related genes, including N‑cadherin, tenascin‑C and COL11A. RRM1 activation also promoted extracellular matrix remodeling and mesenchymal features, which enhanced the migratory invasiveness and malignant potential of pancreatic cancer cells. The present results demonstrated that RRM1 has a critical role in the biological gene program that regulates the extracellular matrix, which promotes the aggressive malignant phenotype of pancreatic cancer.

Keywords: ECM remodeling; RRM1; gemcitabine resistance; histone acetylation; pancreatic cancer.

MeSH terms

  • Acetylation
  • Antineoplastic Agents*
  • Drug Resistance, Neoplasm*
  • Extracellular Matrix*
  • Gemcitabine
  • Histones
  • Humans
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / genetics
  • Ribonucleoside Diphosphate Reductase* / genetics
  • Tumor Microenvironment

Substances

  • Antineoplastic Agents
  • Gemcitabine
  • Histones
  • Ribonucleoside Diphosphate Reductase
  • RRM1 protein, human

Grants and funding

The present study was supported by JSPS KAKENHI Grant-in-Aid for Scientific Research (C) (grant. no. 21K08793).